CD8A and B-cell chronic lymphocytic leukemia: Regarding sArginase-1, mutated IGHV patients display higher values than unmutated IGHV patients, which is in contrast with the previously reported level of sArginase-1 in TME, as it is involved in the stabilization of Treg T cells, generating protection for B-CLL cells and suppressing CD8+ T cells (34).